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The termini of hepatitis A virus (HAV) mature proteins have been assigned mainly by their homology to other picornaviruses
and their apparent electrophoretic mobility; the proposed coding sequence for VP1 is supposed to encompass 900 nucleo-
tides from position 2208 to 3107 of the HAV genome. In order to further characterize this protein, we analyzed the in vitro-
and in vivo-synthesized translation products of the putative VP1 gene. cDNA coding for full-length VP1 was cloned under
the control of a T7 promoter in pTF7-5; the resulting plasmid (pTF7-5/VP1) was used for both synthesis of RNA to program
rabbit reticulocyte lysates and construction of a recombinant vaccinia virus (rvv/T7-VP1). Immunoblot analysis and immuno-
precipitation using antisera raised against a synthetic peptide corresponding to amino acids 13 to 33 of VP1 (13-33/VP1)
led to identification of a 37-kDa protein in lysates of in vitro translated VP1 and rvv/T7-VP1-infected HFS cells, whereas a
33-kDa protein was detected with purified virions and in lysates of HAV-infected HFS cells. Because the antiserum used
was directed against an amino-terminal part of VP1 and the amino terminus of VP1 is identified by sequence analysis, these
results show that VP1 present in the HAV virions and infected cells is shorter than previously proposed and suggest that
the real carboxy terminus of VP1 is approximately 40 amino acids upstream. In order to limit the possible carboxy-terminal
sites in the predicted region, we investigated in vitro synthesized translation products of a set of constructs with C-termini
ending at potential cleavage sites for viral proteases 3C. The construct containing the nucleotides from position 2208 to
3026 codes for a protein (1-273/VP1) which exhibits the same electrophoretic mobility as VP1 synthesized by HAV in vivo.
q 1995 Academic Press, Inc.
Hepatitis A virus (HAV), a picornavirus (1), is the caus- dicted termini of the proteins within the polyprotein as
possible targets for protease 3C and may therefore giveative agent of an acute liver disease in humans. Although
HAV shares the common features of the picornavirus evidence that the predicted termini of the individual pro-
teins are correct (11, 12).family of being a small, unenveloped virus with a positive-
It is proposed that the open reading frame coding forstrand genome, it differs significantly from the other
structural protein VP1 (VP1-ORF) is situated between nu-members of this family with regard to its growth, particle
cleotides 2208 and 3107 of the HAV genome (5). Thestability, and pathophysiology (2–4) and is therefore clas-
amino terminus of VP1 is determined by amino acid se-sified within the recently additionally created hepatovirus
quence analysis (8), whereas the carboxy terminus isgenus. The HAV genome is composed of approximately
assigned by homology to other picornaviruses, the7500 nucleotides and codes for a polyprotein which is
presence of a potential cleavage site for the virus-posttranslationally cleaved into mature proteins. Little is
encoded protease 3C, and the apparent molecular massknown about the steps involved in the processing of the
of 33 kDa.polyprotein; the termini of most of the individual proteins
In order to investigate functional and immunologicalhave been assigned by homology to other picornaviruses
properties of VP1, we cloned the putative gene for VP1,(5, 6) and apparent electrophoretic mobility (7). The pro-
translated it in vitro, and expressed it in cell culture usingposed N-termini of 1B (VP2), 1D (VP1), and 3C have been
vaccinia virus as expression system. The P1 region ofconfirmed by amino acid sequence analysis (8–10). Stud-
HAV strain HM175 (HAV-HM175) was composed fromies with synthetic polypeptides and natural substrates
plasmids pHAVL1307 and pHAVLB228 (13) and used ashave identified the proposed cleavage sites at the pre-
template to isolate the proposed VP1 gene (nucleotides
2208–3107) by PCR (14). The synthetic oligonucleotide1 To whom correspondence and reprint requests should be ad-
primers used, 5*-GGTTAACATGGTTGGAGATGATTC-dressed.
TGGAGGTTT-3* and 5*-GGAATTCTACTCAAATCTTTT-2 Present address: Department of Virology, University of Bremen,
Argonnenstr. 3, D-28211 Bremen, Germany. Fax: 421-218-4266. ATCTTCCTCTG-3*, provided eukaryotic consensus nu-
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with HAV and in purified virions (3) (Fig. 2), was used to
immunoprecipitate in vitro translated VP1 (20). Anti-(13-
33/VP1) serum recognized the 37-kDa protein (Fig. 1, lane
3), whereas preimmune serum (Fig. 1, lane 1) and anti-
KLH serum (not shown) did not immunoprecipitate any
protein from the same rabbit reticulocyte lysates. These
results showed that the 37-kDa protein was indeed VP1.
Translation of the same 37-kDa protein was obtained
with transcripts of VP1 genes isolated and cloned inde-FIG. 1. Translation of the proposed gene coding for VP1 in rabbit
pendently and regardless of whether a T7 or a SP6 pro-reticulocyte lysate extracts and in recombinant vaccinia virus-infected
cells. Extracts containing in vitro and in cell culture translated [35S]- moter was used to drive the synthesis of mRNA (data
methionine-labeled proteins were analyzed with 10% SDS–PAGE and not shown). This indicated that the length of the VP1
fluorographed. Rabbit reticulocyte lysates programmed with in vitro protein, which is encoded by the assumed VP1-ORF and
synthesized VP1 mRNA (lane 11) were immunoprecipitated with preim-
resulted in a 37-kDa protein despite its calculated molec-mune serum (lane 1) or anti-(13-33/VP1) serum (lane 3). Extracts of
ular mass of 33 kDa, was not due to transcription ordifferent cell lines infected with recombinant vaccinia virus rvv/T7-VP1
were immunoprecipitated with preimmune serum (HFS cells, lane 2) translation artifacts.
or anti-(13-33/VP1) serum (HFS cells, lane 4; CV-1 cells, lane 5; MDBK For expression of the putative VP1-ORF in primate cells
cells, lane 6), as well as with anti-vaccinia serum (HFS cells, lane 10). we used the vaccinia virus system. Recombinant vaccinia
Immunoprecipitation with anti-(13-33/VP1) serum was also performed
virus rvv/T7-VP1 was constructed using standard tech-with extracts of HFS cells infected with VactkCS43-VP1 (lane 7) and
niques (21). Cytoplasmatic extracts of [35S]methionine-VactkCS43-VP1L (lane 8), which contains the leader sequence of gp
IV of bovine herpes virus-1 upstream of the VP1 gene and served as labeled HFS cells infected with vaccinia WR strain or rv v/
control for the expression of the VP1 gene under control of the vaccinia T7-VP1 were immunoprecipitated with either preimmune
virus 7.5 promoter. The two proteins detected in lane 8 represent the serum or anti-(13-33/VP1) serum and analyzed by SDS–
glycosylated and nonglycosylated forms of protein VP1L. Furthermore,
PAGE. Anti-(13-33/VP1) serum immunoprecipitated a 37-extracts of HFS cells infected with vaccinia virus strain WR were immu-
kDa protein from extracts of rvv/T7-VP1-infected cellsnoprecipitated with anti-(13-33/VP1) serum (lane 9).
(Fig. 1, lanes 4–6), but none from extracts of vaccinia
WR-infected cells (Fig. 1, lane 9); preimmune serum did
not recognize any protein in extracts of rvv/T7-VP1-in-cleotides for translation initiation (15) as well as initiation
(ATG) and termination (TAG) codons for translation. The fected cells (Fig. 1, lane 2). It should be pointed out that
the 37-kDa protein immunoprecipitated from extracts ofamplified VP1 gene was introduced into plasmid pTF7-5
under control of the T7 promoter and named pTF7-5/VP1; rvv/T7-VP1-infected cells comigrated with the in vitro-
translated VP1 (Fig. 1, compare lanes 4–6 with lanes 3all constructs as well as the VP1 gene were verified by
nucleotide sequencing using the dideoxy method (16). It and 11). Similar results were obtained with recombinant
vaccinia viruses expressing the VP1 gene under controlshould be pointed out that pTF7-5/VP1 allows not only
in vitro synthesis of run-off transcripts of the VP1 gene, of the vaccinia virus 7.5 K promoter (VactkCS43-VP1; (22))
(Fig. 1, lane 7); moreover, expression of the 37-kDa pro-but also homologous recombination into the tk gene of
vaccinia virus (17). tein was also observed in CV-1 cells (Fig. 1, lane 5) and
MDBK cells (Fig. 1, lane 6) infected with both types ofIn order to translate VP1 in vitro, pTF7-5/VP1 was used
both linearized with the restriction enzyme EcoRI, which recombinant vaccinia virus carrying the putative gene for
VP1. Immunoblot analysis (19) gave the equivalent re-cuts 11 bases downstream of the VP1 termination codon,
and without linearization for transcription with T7 RNA sults (not shown). These results indicated that translation
of the 37-kDa protein was independent of both recombi-polymerase under reaction conditions defined by the
manufacturer (Promega, Biotech). Rabbit reticulocyte ly- nant vaccinia virus and cell line used in the expression
of the putative VP1 gene.sates (NEN) were programmed with the VP1 transcripts
in the presence of [35S]methionine in accordance with the In order to investigate whether a 37-kDa protein was
also present in HAV-infected HFS cells, cytoplasmic ex-manufacturer’s instructions and analyzed by 10% SDS –
PAGE (18). cRNA synthesized both on linearized and on tracts were made at different times after infection and
characterized by immunoblotting with the anti-(13-33/nonlinearized plasmids directed the synthesis of a 37-
kDa protein (Fig. 1, lane 11), whereas no proteins were VP1) serum. Figure 2A shows that two proteins with ap-
parent molecular masses of 40 and 33 kDa were recog-observed in the absence of VP1 transcripts (not shown).
For further characterization of the 37-kDa protein, we nized by the anti-peptide serum at 4 (lane 3) and 7 days
(lane 4) after infection, whereas only the 33-kDa proteinraised antibodies against a synthetic peptide represent-
ing an amino-terminal part of VP1. Rabbits were immu- was detected 14 days postinfection (lane 5 and Fig. 2B,
lane 1). Proteins were not detectable from cell extractsnized with the peptide corresponding to residues 13 to
33 of VP1 (13-33/VP1) conjugated to KLH (19), and this 1 and 3 days after infection (lanes 1 and 2), probably
because of low levels of expression during the first partantiserum, which recognized VP1 in HFS cells infected
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FIG. 2. Kinetics of expression of VP1 in HFS cells infected with HAV and detection of VP1 in purified virions. (A) Cytoplasmic extracts of HFS
cells infected with HAV were prepared at different times after infection and analyzed with anti-(13-33/VP1) serum by immunoblotting. Cell extracts
were prepared on Days 1 (lane 1), 3 (lane 2), 4 (lane 3), 7 (lane 4), and 14 (lane 5) postinfection. Cytoplasmic extracts of uninfected HFS cells (lane
6) and recombinant vaccinia virus rvv/T7-VP1-infected HFS cells (lane 7) were used as reference. Migrations of molecular weight markers are
indicated. (B) Immunoblot analysis of HFS cells infected with HAV on Day 14 postinfection (lane 1), purified virions (lane 2), and HFS cells infected
with rvv/T7-VP1 (lane 3) with anti-(13-33/VP1) serum.
of the replication cycle of HAV, nor from uninfected cell masses of 36 and 38 kDa have been demonstrated (2,
12). The occurrence of these proteins seems to dependextracts (lane 6). Using isolated virions, only the 33-kDa
protein could be detected (Fig. 2B, lane 2). The 37-kDa on the cell culture system and/or the HAV strain used.
In HFS cells infected with HAV-GBM (26) they were notprotein detected in cytoplasmic extracts of rvv/T7-VP1-
infected cells (Fig. 1, lanes 4–6; Fig. 2A, lane 7; and Fig. detectable (Fig. 2), whereas in FRhK-4 cells infected
with HAV-HM175 (27) the two proteins were traceable2B, lane 3) migrated between the 33- and the 40-kDa
proteins (Fig. 2A, compare lane 7 with lanes 3 and 4), in small amounts (Fig. 3, lanes 6 and 9). It might be
possible that under the influence of specific host cellwhich indicated that it was a different protein not seen
in HAV-infected cells and HAV virions. Equivalent results factors either the VP1 precursor is cleaved incorrectly
or the released VP1 is subsequently modified. As bothwere obtained analyzing the extracts of [35S]methionine/
cysteine-labeled HFS cells infected with HAV by immuno- in isolated virions and in infected HFS cells none of
these additional proteins were identified, they are ofprecipitation (data not shown). According to findings from
cardioviruses (23) and aphtoviruses (24), the 40-kDa pro- uncertain significance in the replication cycle of HAV.
The mechanism involved in processing of the HAV poly-tein could represent a VP1-2A precursor that is further
cleaved into a 33-kDa mature VP1 protein. The fact that protein and release of mature VP1 is not clear. Among
picornaviruses there are two distinctive ways in whichthe 37-kDa protein was not detectable in HAV-infected
cells at different times after infection and in purified viri- VP1 is released from the polyprotein: in enteroviruses
and rhinoviruses primary cleavage occurs between VP1ons indicated that the putative full VP1 is larger than the
mature VP1. and 2A which is mediated by the latter, whereas in
cardio- and aphtoviruses primary cleavage occurs be-The amino terminus of VP1 is determined by amino
acid sequencing (8), whereas the carboxy terminus is tween 2A and 2B, and subsequently the VP1-2A precur-
assigned by both homology to other picornaviruses and
the presence of a potential cleavage site for 3Cpro (5,
25). Our finding that translation of the putative VP1-ORF
in vitro in reticulocyte lysates and in cell culture using
the vaccinia virus system resulted in a protein with an
apparent mass of 37 kDa, rather than in the 33-kDa
VP1 molecule seen in purified virions and HAV-infected
cells, suggests that processing of VP1 occurs within the
FIG. 3. Translation of coding sequences for VP1 ending at potentialassumed ORF. Proof of the 40-, 37-, and 33-kDa proteins
cleavage sites for 3Cpro within the proposed C-terminus in rabbit reticu-
with antiserum against 13-33/VP1 peptide showed that locyte lysate. In vitro synthesized, [35S]methionine-labeled proteins rep-
these proteins share N-terminal sequences. Therefore, resenting 1-254/VP1 (lane 1), 1-264/VP1 (lanes 2 and 8), 1-273/VP1
(lanes 3 and 10), 1-285/VP1 (lane 4), and 1-300/VP1 (lane 5), as wellprocessing should occur at the C-terminus of VP1’s pu-
as cytoplasmic extracts of FRhK-4 cells infected with HAV (lanes 6 andtative ORF.
9) and of uninfected FRhK-4 cells (lane 7), were immunoprecipitatedAlthough the 37-kDa protein has never been detected
with anti-(13-33/VP1) serum, analyzed with 10% SDS–PAGE, and fluoro-
in HAV-infected cells, we cannot rule out the possibility graphed. In addition to the 40- and 33-kDa proteins, the 38- and 36-
that it has a short half-life. Two VP1 containing proteins kDa proteins could also be detected when using cytoplasmic extracts
of FRhK-4 cells infected with HAV.in HAV-infected cell lysates with approximate molecular
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sor is cleaved by 3Cpro (28). In addition to the assump- which led to the assumption that host cell factors are
involved. The release of VP1 from its 40-kDa precursortion that host cell factors are involved in the release of
VP1 (12), it has been suggested that release of VP1 of through cleavage between the Glu – Ser proposed by
us, which represents amino acids 764 and 765 of theHAV resembles processing of cardio- and aphtoviruses
and that the 40-kDa protein represents a VP1-2A precur- HAV polyprotein, may imply that 3Cpro alone is sufficient
to perform the release of VP1 and that the low specificitysor that is cleaved by 3Cpro (29, 30) at a Glu – Ser linkage
resulting in 1-300/VP1. Within the C-terminal 50 amino of protease 3C for this junction sequence is responsible
for the relative stability of the VP1 precursor, as in theacids of the proposed VP1, we identified five potential
cleavage sites for picornaviral proteinases 3C (31) con- case of 3A/3B, which is separated by the amino acid
pair Glu – Gly.sisting of Gln – Ser (254-255/VP1), Leu – Asn (264-265/
VP1), Glu – Ser (273-274/VP1), Ala – Gly (281-282/VP1), Finally, definitive identification of the C-terminus of VP1
can only be achieved by amino acid sequencing. Conse-and Glu – Ser (285-286/VP1), respectively. In order to
compare the proteins, which would result from cleavage quently, further studies will be required for determining
the authentic termini of VP1 and the identification of theat these sites, and the authentic VP1 relative to their
electrophoretic mobility, we cloned the corresponding protease(s) involved in its processing.
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